NCT07032103

Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV

A Prospective Study for Patients With Lymphoma at the Samsung Medical Center

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 2,000 (estimated)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.

Detailed description

The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows. 1. Registration after informed consent. 2. Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood 3. Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood 4. Regular monitoring disease status and update of survival status 5. Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood

Conditions

• Lymphoma

Interventions

Type	Name	Description
DRUG	Immunochemotherapy	Systemic chemotherapy with curative intent

Timeline

• Start date: 2022-06-01
• Primary completion: 2028-12-30
• Completion: 2028-12-30
• First posted: 2025-06-22
• Last updated: 2025-06-22

Locations

1 site across 1 country: South Korea

Regulatory

• FDA-regulated drug study